At the news
? NEUTRALIMPACT 3/10 EFFECT filed Apr 13, 2026 at 00:15 ET
Oruka Therapeutics' $1 billion shelf registration (S-3) has become effective, allowing the company to sell common stock, preferred stock, depositary shares, or warrants from time to time. This creates a potential for future dilution, though no immediate offering has been announced.
- S-3 shelf registration effective as of April 10, 2026
- Registration allows for up to $1 billion in securities to be offered
- Securities may include common stock, preferred stock, depositary shares, or warrants
- Offerings can occur at any time over the next three years, with terms disclosed in future prospectus supplements
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access